Compare Adaptive Biotechnologies Corp (ADPT) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Petróleo Brasileiro SA — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Petróleo Brasileiro SA trades at $17.13 (market cap $102.10B). The key difference: Petróleo Brasileiro SA is far larger — about 30.7× Adaptive Biotechnologies Corp's market cap, and Petróleo Brasileiro SA pays a 10.58% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PBR | |
|---|---|---|
Market Cap | $3.33B | $102.10B |
Sector | Health | Technology |
52-Week High | $22.37 | $22.03 |
52-Week Low | $10.24 | $11.54 |
Enterprise Value | $3.19B | $164.64B |
Dividend Yield | — | 10.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PBR trades at $16.26, up 0.93% with a bearish technical outlook despite strong fundamentals. The company reported $488.72B revenue and $107.58B net income for 2025, with attractive valuation metrics including a 5.18 P/E ratio and 24.94% ROE. Recent earnings showed mixed results with a Q1 2026 miss but strong beats in previous quarters. Analyst consensus remains positive with a $23.90 price target, while technical indicators show bearish momentum with key support at $16.
PBR presents a compelling value opportunity with deep discount valuation and robust cash flow generation supporting substantial dividends. However, recent earnings volatility and bearish technical signals suggest near-term pressure. The stock's 46% upside to consensus target offers significant potential, but investors should monitor execution on production growth targets and global oil price stability as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
